Research programme: sodium/hydrogen exchanger-1 inhibitors - sanofi-aventis
Alternative Names: AVE 4454; AVE 4890; Na+/H+ exchanger-1 inhibitors; NHE-1 inhibitorsLatest Information Update: 16 Jul 2016
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Sodium-hydrogen antiporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Heart failure
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Europe
- 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in Europe
- 19 Apr 2005 Preclinical trials in Congestive heart failure in Europe (unspecified route)